Business
TherapeuticsMD Announces Multiple Presentations Related to IMVEXXY® and BIJUVA® at the 2019 Annual Meeting of the North American Menopause Society
BOCA RATON, Fla.--(BUSINESS WIRE)-- TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced the schedule of two oral
About this update from Therapeuticsmd, Inc.
[{"type":"text","content":" BOCA RATON, Fla.--(BUSINESS WIRE)--\nTherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced the schedule of two oral presentations and five posters that will be presented at the 2019 Annual Meeting of the North American Menopause Society (NAMS) being held on September 25-28, 2019, related to IMVEXXY® (estradiol vaginal inserts) and BIJUVA® (estradiol and progesterone capsules).\n\n\n“We are excited to report results from the REPLENISH Phase 3 trial for BIJUVA that show improvements in several sleep parameters, including sleep disturbances, in menopausal women with moderate to severe vasomotor symptoms taking BIJUVA as compared to placebo. In addition, we will present data for BIJUVA showing a consistency of effect for improvements in the frequency and severity of vasomotor symptoms in different subpopulations, regardless of age or body mass index,” said TherapeuticsMD Chief Medical Officer Sebastian Mirkin, M.D.\n\n\nAdditionally, two oral presentations will review the growth of the vulvar vaginal atrophy (VVA) market and patient acceptability data, including patient satisfaction and preference, for IMVEXXY.\n\n\nThe posters and presentations will be made available on the Investors & Media section of the company’s website at www.therapeuticsmd.com.\n\n\nOral Presentations\n\n\nDate: September 27, 2019\nTime: 4:15 - 4:30 pm\n\n\nTitle: Growth of the Vulvar Vaginal Atrophy (VVA) Therapy Market\n\n\nDate: September 27, 2019\nTime: 4:30 - 4:45 pm\n\n\nTitle: Postmenopausal Women Using a Softgel Estradiol Vaginal Insert to Treat Moderate-to-Severe Dyspareunia were Satisfied with it and Preferred it over a Previous Therapy\n\n\nPosters \n\n\nDate: September 25, 2019\nTime: 6:00 - 7:00 pm\n\n\nTitle: Uterine Bleeding Rates with Hormone Therapies in Menopausal Women with Vasomotor Symptoms (Poster P-55)\n\n\nTitle: Baseline Estradiol Levels in Postmenopausal Women (Poster P-11)\n\n\nTitle: Nonsmokers May Benefit from Lower Doses of an Oral 17β-Estradiol/Progesterone Capsule — Data from the REPLENISH Trial (Poster P-12)\n\n\nTitle: Oral 17β-Estradiol/Progesterone (E2/P4) Improved Sleep Outcomes in the REPLENISH Trial (Poster P-31)\n\n\nTitle: E2/P4 Capsules Effectively Treat Vasomotor Symptoms Irrespective of Age and BMI (Poster P-6)\n\n\nPlease see the Full Prescribing Information, including indi...